Regenacy Pharmaceuticals

A five-person lab with a molecule worth millions

Walk into Regenacy's world and you won't find a campus. You'll find a clinical-stage biopharmaceutical company small enough to fit around one conference table, sitting on a drug that has already moved through patients in a Phase 2 trial. The headcount reads like a startup. The pipeline reads like a mid-size pharma. That gap is the whole story.

The work is unglamorous and exact. Regenacy develops oral, isoform-selective histone deacetylase inhibitors - the kind of sentence that empties a room at parties and fills one at scientific conferences. Translated: most drugs that touch this family of enzymes hit all of them at once, like turning off a city's power to fix one streetlight. Regenacy aims for the single streetlight.

Diabetic neuropathy has plenty of pills. None of them work very well.

Painful diabetic peripheral neuropathy is one of those conditions medicine has mostly learned to manage by apologizing for. Millions of people live with burning, numb, electric feet. The standard toolkit - gabapentinoids, duloxetine, capsaicin patches - dulls the signal. It does nothing to the underlying nerve.

The reason is mechanical, in the most literal sense. Nerves are long, and they depend on an internal transport system - microtubule "highways" - to ferry proteins and organelles from one end to the other. In neuropathy, that traffic seizes up. Regenacy's bet is that an enzyme called HDAC6 is sitting in the middle of the jam, and that inhibiting it lets the trucks move again.

Born from a buyout, built on a decade of stubbornness

Regenacy did not start from a blank page. In 2016, the pharmaceutical giant Celgene acquired Acetylon Pharmaceuticals, a company that had spent years building selective HDAC inhibitors. The cancer assets went to Celgene. Everything else - including the rights to a molecule called ricolinostat for non-cancer diseases - became the seed of a new company.

That company was Regenacy. Leading it, as President and CEO from 2017, is Simon S. Jones, Ph.D., who had been chasing selective HDAC inhibitors since joining Acetylon back in 2009. The continuity is the point. Most biotechs are founded on a fresh hypothesis. Regenacy was founded on a refusal to let a good one die in an acquisition.

One enzyme, two fronts, a portfolio of restraint

Ricolinostat is an orally bioavailable, first-in-class selective inhibitor of HDAC6. The selectivity is the selling point. Older HDAC inhibitors were chemical sledgehammers - effective in some cancers, but with side-effect profiles that made chronic, daily use a hard sell. Regenacy's thesis is that hitting one isoform, cleanly, buys you a safety margin gentle enough to treat a chronic disease for years.

Behind ricolinostat sits a second, quieter program: a proprietary portfolio of selective HDAC1,2 inhibitors aimed at blood diseases like sickle cell and beta-thalassemia, and at cognitive dysfunction in disorders such as Alzheimer's. In 2017, Regenacy presented preclinical data showing HDAC1,2 inhibition improved cognitive function in Alzheimer's mouse models. It is the kind of result that makes a small company look surprisingly deep.

The money followed the mechanism

Ideas are cheap in biotech. Trials are not. The signal that Regenacy's thesis is more than a slide deck is that investors funded it twice, through one of the harder fundraising climates the sector has seen. A $30 million Series A in 2020 was co-led by Cobro Ventures and Taiwania Capital Management, with a cross-border syndicate including 3E Bioventures Capital and VIVA Biotech Holdings. A $9.3 million Series B followed in 2022, alongside the news that the Phase 2 neuropathy trial had finished enrolling patients.

There is also the matter of geography. The 2020 joint venture with 3E Bioventures to develop ricolinostat in China is the kind of move that signals ambition disproportionate to headcount - a five-person company quietly planning for two continents.

It helps to be clear about who this is for. The end user is not a hospital procurement office or a data team. It is a person with diabetes whose feet burn at night, whose current options are drugs borrowed from epilepsy and depression that dull the noise without touching the wire. If ricolinostat works as designed, the thing it offers them is unusual in this category: not a stronger painkiller, but a daily oral pill aimed at the nerve itself. The competition, for now, is the absence of anything better.

Regenerate. Acetylate. The name is the plan.

Pull the company name apart and you get its strategy: regenerate + acetylation. Protein acetylation is the chemical switch Regenacy's drugs are built to restore. The mission statement reads like a thesis defense - to regenerate normal biological function by restoring protein acetylation, with selective inhibitors that promise superior safety over the blunt instruments that came before.

It is an unusually honest mission for a sector fond of grander language. Regenacy is not promising to cure everything. It is promising to switch one specific thing back on, and to do it cleanly enough that a patient can live with the drug. In an industry that rewards hype, restraint is almost a brand.

That restraint shows up in the business model too. Regenacy is not trying to build a sprawling commercial pharma overnight. It advances a small number of patent-protected molecules through trials, funds the work with focused venture rounds, and uses regional deals - like the China joint venture - to extend reach without ballooning the team. It is a structure designed to keep the science, not the org chart, at the center.

If the bet pays off, the table gets bigger

The reason a five-person company is worth paying attention to is leverage. If selective HDAC6 inhibition genuinely repairs nerve transport, ricolinostat doesn't stop at diabetic neuropathy. The same mechanism reaches toward chemotherapy-induced neuropathy and inherited conditions like Charcot-Marie-Tooth. And the HDAC1,2 portfolio quietly extends the logic into blood diseases and the brain.

That is the shape of an asymmetric bet. A small team, a modest raise, a single clean mechanism - and a list of diseases long enough that even partial success rewrites the conference table from one chair to many.

Return, then, to where we started: that room small enough to fit one conference table, holding a drug that has already passed through patients. The numbers haven't caught up to the ambition yet. But Regenacy's whole argument is that they don't need to be large to be right. They just need one selective enzyme inhibitor to do exactly what it was designed to do - and let the nerves do the rest.

Links & sources